Cost effectiveness of antenatal anti‐D prophylaxis

Sandra Vick, John Cairns, Stan Urbaniak, Charles Whitfield and Alaeddin Raafat

Health Economics, 1996, vol. 5, issue 4, 319-328

Abstract: This paper estimates the incremental cost‐effectiveness of providing antenatal anti‐D prophylaxis in varying dose sizes to either primigravidae or all Rh D negative women. It presents a model for calculating the net cost per 1000 ‘at risk’ women based on the costs of anti‐D prophylaxis and the future NHS costs avoided. Incremental cost‐effectiveness is measured in terms of the net cost per Rh D‐alloimmunization and the net cost per Rh HD loss prevented. Programmes for Rh D negative primigravidae are more cost‐effective than the same dose protocol extended to all Rh D negative women. The 1 × 1250 iu programme is the most cost‐effective option.

Date: 1996
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1002/(SICI)1099-1050(199607)5:43.0.CO;2-6

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:5:y:1996:i:4:p:319-328

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().